Island Pharmaceuticals
ASX:ILACamberwell, Australia· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileOverview
Australian biotech repurposing antivirals for dengue and other vector‑borne diseases, with a Phase 2a/b trial of ISLA‑101.
Infectious DiseasesVirologyAntiviral
Technology Platform
Drug repurposing of orally administered antivirals with known safety profiles to accelerate development for unmet infectious disease indications.
Opportunities
Successful Phase 2 data for ISLA‑101 could enable fast‑track regulatory pathways and partnership deals; acquisition of galidesivir would broaden the antiviral portfolio and address emerging RNA virus threats.
Risk Factors
Clinical trial failure or safety concerns for ISLA‑101; challenges in completing the galidesivir acquisition; limited cash runway as a pre‑revenue company.
Competitive Landscape
Competes with other antiviral developers and repurposing firms; differentiation lies in its oral formulation and rapid development timeline leveraging known safety data.